• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis

byBryant LimandKiera Liblik
August 26, 2022
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Two randomized clinical trials showed that intravenous ublituximab reduced relapse rate and the number of brain lesions in multiple sclerosis patients compared to oral teriflunomide.

2. Ublituximab treatment was associated with infusion-related reactions.

Evidence Rating Level: 1 (Excellent)

Study Rundown: B cell activity plays an important role in multiple sclerosis pathogenesis. B-cell antigen-specific monoclonal antibodies have demonstrated therapeutic effects for patients with multiple sclerosis. In a previous phase two trial, ublituximab, a novel B-cell antigen-specific monoclonal antibody, induced B-cell depletion and reduced relapse rate among patients with relapsing multiple sclerosis. Using data from two randomized clinical trial (ULTIMATE I and ULTIMATE II), the present study examined the efficacy and safety of intravenous ublituximab in patients with relapsing multiple sclerosis, compared to teriflunomide. Participants in the ublituximab group received intravenous ublituximab and oral placebo. Participants in the teriflunomide group received oral teriflunomide once daily and intravenous placebo on the same schedule as that in the ublituximab group. The annualized relapse rate was significantly lower in the ublituximab group compared to the teriflunomide group. The ublituximab also had a significantly lower number of gadolinium-enhancing lesions, a marker of active disease. However, close to half of the participants in the ublituximab group experienced infusion-related reactions. As a limitation, the results may not be generalizable to all populations, as participants were predominantly from Eastern Europe. The efficacy of ublituximab was also not compared to other multiple sclerosis therapies.

Click to read the study in NEJM

In-Depth [randomized control trial]: Results from two identical phase three randomized clinical trials were reported (ULTIMATE I (n=549) and ULTIMATE II (n=545)). Adults aged 18 to 55 with a diagnosis of relapsing multiple sclerosis were randomized in a 1:1 ratio to receive intravenous ublituximab and oral placebo or oral teriflunomide and intravenous placebo. Intravenous ublituximab was administered on days 1 and 15 and at weeks 24, 48, and 72. Oral teriflunomide was administered once daily. Participants were monitored for 96 weeks, followed by a 20-week monitoring period. The adjusted annual relapse rate over 96 weeks for the ublituximab and teriflunomide groups were 0.08 and 0.19 (rate ratio, 0.41; 95% Confidence Interval [CI], 0.27 to 0.62; p<0.001) in the ULTIMATE I trial and 0.09 and 0.18 (rate ratio, 0.51; 95% CI, 0.33 to 0.78; p=0.002) in the ULTIMATE II trial. The mean total number of gadolinium-enhancing lesions per MRI scan was significantly lower in the ublituximab group compared to the teriflunomide group for both ULTIMATE I (rate ratio, 0.03; 95% CI, 0.02 to 0.06; p<0.001) and ULTIMATE II (rate ratio, 0.04; 95% CI, 0.02 to 0.06; p<0.001) trials. By the end of the trial, CD19+ B cell counts were reduced by 97% in the ublituximab group compared to 18% in the teriflunomide group. Participant disability was pooled from both trials for analysis. There were no significant differences between groups in the proportion of participants with worsening disability at 12 or 24 weeks. Brain volume at six months was also not significantly different between groups. There were no significant differences between groups in the proportion of participants with infections or at least one adverse event. The most common adverse event in the ublituximab and teriflunomide groups were infusion-related reactions (47.7%) and headache (26.6%), respectively. While ublituximab is a promising treatment for reducing relapse for multiple sclerosis, larger and longer trials are necessary to understand the efficacy and safety of ublituximab compared to existing treatments.

Image: PD

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: B-cell antigen-specific monoclonal antibodieschronic diseasegadolinium-enhancing lesionsmultiple sclerosisneurologyrelapsing multiple sclerosisteriflunomideublituximabULTIMATE IULTIMATE II
Previous Post

Youth-onset type 2 diabetes may have increased sharply during the COVID-19 pandemic

Next Post

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Next Post
2 Minute Medicine Rewind January 28, 2019

Olokizumab is noninferior to adalimumab for the treatment of rheumatoid arthritis

Nonmedical expenses of pediatric hospitalizations have disproportionate effects

Childhood cash supplementation program may improve outcomes into adulthood

Medical vaccine exemptions increase after elimination of nonmedical exemptions

COVID-19 vaccination not associated with adverse obstetric outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options